68 results about "Cell Maturation" patented technology

The present disclosure provides methods of treating multiple myeloma in a patient in need thereof comprising administering a gamma secretase and a B-cell maturation antigen (BCMA)-directed therapy to the patient.

The disclosure concerns a method of treating cancer, especially, such as multiple myeloma, involving the combination of an anti-BCMA (B cell maturation antigen) antibody, Belantamab mafodotin -GSK2857916- and a gamma-secretase inhibitor, e.g., nirogacestat -PF03084014-. The disclosure also relates to dosages, duration of treatment and time lapses between administration of the anti-BCMA antibody and the gamma-secretase inhibitor.

The invention relates to the field of cell biology, and particularly relates to a preparation method of a pancreatic cancer-related antigen-loaded polypeptide, which is characterized in that factors such as GM-CSF, IL-4, IFN-gamma, TNF-alpha, IL-1beta, IL-6, PGE2, Poly I: C, R848 and the like are added to promote mononuclear cells to be activated into DC cells, pancreatic cancer PANC-1, MIA PaCa-2, BxPC-3, KP4 and SW1990HM antigens are loaded, and not only is DC cell maturation promoted, but also pancreatic cancer-related antigens are loaded. The positive rate of CD83 + CD86 of the DC cells cultured by the method is 94.16%, and the secretion amount of IL-12p70 in a cell supernatant is (645.38 + / -36.49) pg / mL. By adopting the culture method disclosed by the invention, the maturation rate of the DC cells can be improved while the DC cells are activated, so that the culture method for promoting the maturation and amplification of the DC cells loaded with the pancreatic cancer antigen is achieved.

Provided are humanized nanobody targeting BCMA and a use thereof. The nanobody is capable of binding to B-cell maturation antigen (BCMA), and the isolated antigen-binding protein comprises at least one CDR in an antibody heavy chain variable region (VH). Provided are a chimeric antigen receptor, a fusion protein, a cell and a nucleic acid molecule comprising the antigen-binding protein, and a use thereof in the treatment of tumors.

Provided are a reagent combination or a kit for constructing an embryoid and the use thereof. The reagent combination or the kit can be used for inducing a stem cell to produce a blastocyst-like lineage precursor cell, a blastocyst-like cell and / or an embryoid, which are based on small-molecule induction and independent of transgenes, and have a single cell source. The produced blastocyst-like lineage precursor cell and blastocyst-like cell have a full blastocyst lineage, and are seed cells having balanced developmental competence and totipotency, which solves the problem of unbalanced cell maturation in the prior art. The produced embryoid is highly similar to natural embryos in terms of morphological characteristics and transcriptomic characteristics, has the capability of highly reproducing post-implantation embryonic development and / or gastrulation, which is beneficial for research on embryonic development in vitro. The method for inducing the stem cell to produce the blastocyst-like lineage precursor cell, the blastocyst-like cell and / or the embryoid by using the reagent combination or the kit is simple, and has high applicability and high embryoid construction efficiency.

The invention relates to a multi-metal element nano-aluminum adjuvant and a preparation method and application thereof, the nano-aluminum adjuvant is a nano-particle containing an aluminum element and at least one metal element selected from magnesium, zinc and calcium, the nano-particle has a layered crystal structure, and the particle size is distributed in a range of 20-2000 nm. The difunctional nano-aluminum adjuvant has the beneficial effects that the difunctional nano-aluminum adjuvant is simple and convenient in preparation method, definite in component and uniform in particle size, the particle size of the particles can be manually regulated and controlled, and the difunctional nano-aluminum adjuvant can directly promote antigen presenting cells to be mature and activated and carry out MHC-I or II type antigen presentation.

Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.

This provides a multispecific antibody that binds to BCMA. [Solution] A multispecific human heavy chain antibody (e.g., UniAb) that binds to B cell maturation antigen (BCMA). TM Disclosed are methods for producing such antibodies, compositions comprising pharmaceutical compositions containing such antibodies, and their use for treating disorders characterized by BCMA expression. In one embodiment, a multispecific antibody that binds to BCMA is provided, comprising a first binding unit comprising a variable region comprising a CDR3 sequence having at least 85% sequence identity with a specific sequence.

Provided herein are RNA sequences encoding a chimeric antigen receptor (CAR) comprising a B-cell maturation antigen (BCMA) binding molecule, along with related compositions and methods. In some embodiments, circular RNAs encoding the BCMA binding molecule or BCMA CAR, along with related compositions, methods, and precursors, are described herein. In some embodiments, these compositions comprise a transfer vehicle, e.g., comprising an ionizable lipid described herein.

The application belongs to the technical field of cell detection, and relates to application of SYTOX in detection of maturity of peripheral blood red blood cells and a detection kit method. The application provides application of SYTOX in detection of maturity of peripheral blood red blood cells. SYTOX staining is used for distinguishing red blood cells at different maturity stages of peripheral blood, and has high sensitivity, high accuracy and high consistency, and is efficient, simple and easy to popularize.

The present invention relates to in vitro methods of producing mature dendritic cells, a dendritic cell maturation cocktail, a method of producing mature antigen presenting dendritic cells in vitro, methods of manufacturing vaccines containing mature dendritic cells, antigen-presenting mature dendritic cells produced according to the methods described, vaccines containing the mature antigen-presenting dendritic cells and methods of treatment and used of mature antigen-presenting cells of the invention.

The present application provides methods of treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5) / anti-cluster of differentiation 3 (CD3) bispecific antibodies and anti-B cell maturation factor (BCMA) / anti-CD3 bispecific antibodies.

The present invention relates to a novel marrow infiltrating lymphocytes (MILs) population comprising a chimeric antigen receptor containing a B cell maturation antigen (BCMA) specific binding domain, and a method for preparing the same, and more particularly, to a novel marrow infiltrating lymphocytes (MILs) population comprising a chimeric antigen receptor containing a B cell maturation antigen (BCMA) specific binding domain. Specifically, the present invention provides a novel MILs group having characteristics of target cell specificity due to BCMA CAR and strong cytotoxicity to target cells, and a MILs culture method capable of providing the novel MILs group, the novel MILs group being useful as a novel immune anti-cancer therapy due to a high anti-cancer effect of the novel MILs group prepared by the method.

Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and / or treatment diseases, conditions and disorders.

Provided herein compositions and method of using chimeric antigen receptor (CAR) cell therapies for treating diseases or disorders, such as cancer or autoimmune disorders, including dual CARs that binds to both B-cell maturation antigen (BCMA) and CD19. Polynucleotides, vectors, host cells and methods for producing such dual CARs and cell therapies comprising the dual CARs are also provided herein.

The present disclosure relates to compositions and methods for treating disease using chimeric antigen receptor cells and / or antigen binding domains that target BCMA.

B-cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells. In certain embodiments, the bispecific antibodies of the present invention reduce alloantibody levels and / or reduce calculated panel reactive antibody levels to facilitate solid organ transplantation and / or improve long term graft survival and / or function.

This invention relates to GPRC5D and BCMA-specific chimeric antigen receptors (CARs), specifically providing CARs containing an extracellular antigen-binding domain that binds to a G protein-coupled receptor class C5 group D member (GPRC5D) and B cell maturation antigen (BCMA). The invention also relates to genetically engineered cells expressing such CARs and their use in adoptive cell therapy.

Genetically engineered immune cells (e.g., T cells or NK cells) expressing anti-BCMA, anti-TACI, or anti-BCMA / anti-TACI chimeric antigen receptors and uses thereof in cancer therapy. In some embodiments, the genetically engineered immune cells may be armored CAR-T or CAR-NK cells, which further express an armor polypeptide for enhancing CAR-T or CAR-NK cell features.

Described herein is a hepatocyte maturation composition (Hepatocyte Differentiation Cocktail 6"(HDC6)) comprising a TGF-beta inhibitor, a Notch inhibitor, a cAMP activator, a tryptophan pathway metabolite, a PPAR activator, and a thyroid hormone. Methods for generating mature iPSC-derived hepatocytes and 3D liver spheroids are presented. The 3D liver spheroids described herein are suitable for predicting drug-induced liver injury and identifying a preferred therapeutic agent for an individual.

The invention provides a method for in-vitro amplification and induced activation of iNKT cells, and belongs to the technical field of immune cell preparations. The in-vitro amplification method comprises the following steps: S1, separating peripheral blood PBMCs cells; s2, adding a part of PBMCs into a culture medium I for stimulation culture and irradiation, and separating to obtain irradiated PBMCs; s3, re-suspending the other part of PBMCs cells in a culture medium II, adding alpha-GalCer and IL-2 to stimulate culture, then adding the irradiated PBMCs cells, and amplifying iNKT cells; the induction and activation method comprises the following steps: amplifying the iNKT cells, adding a culture medium III, adding a dasatinib derivative, and inducing the iNKT cells to be mature. According to the method, amplification and induced activation of the iNKT cells can be rapidly promoted, the amplification efficiency is high, the obtained iNKT cells are high in cytotoxicity, the method is safe, and graft versus host reaction is not caused.

Antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor are disclosed. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

The present disclosure provides a use of a substance targeting BRD4 in the preparation of a product related to diabetes. In the present disclosure, it is found that the expression of BRD4 in human diabetic beta cells is significantly reduced, and BRD4 plays an important role in maintaining beta cell maturation and differentiation, and long-term and acute BRD4 deficiency can lead to reduced insulin secretion and down-regulation of differentiation markers, highlighting the key role of BRD4 in pancreatic beta cells, providing a target BRD4 that has a significant impact on diabetes, so that substances targeting BRD4 can help to assess the susceptibility of diabetes, screening, prevention, intervention and treatment of diabetes.

The invention relates to the field of biology, in particular to application of tauroursodeoxycholic acid in preparation of a medicine for promoting function maturation of islet organs. The specific effect of tauroursodeoxycholic acid in promoting functional maturation of iPSC-derived islet-like organs is found and verified for the first time, and a brand new treatment thought is represented. The beta cell functional gene expression and glucose stimulation response capability of the sc-islet can be remarkably improved only by performing TUDCA treatment for 96 hours, and the function maturation period is greatly shortened. The obvious effect can be achieved by adopting the low-dose TUDCA with the concentration of 25-100 ng / mL, the cost is reduced, and the potential toxicity risk is reduced. Key indexes (functional gene expression and glucose response) of beta cell maturation are directly targeted, and a high-quality cell model is provided for research and treatment of diabetes mellitus.

Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.

The invention belongs to the technical field of biological medicines, and discloses application of artemisinene with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction. It is found for the first time that ATT can specifically and efficiently promote human hepatic progenitor cell organoids to differentiate into functional mature hepatic cells, the effect of ATT depends on activation of a cAMP-EPAC signal channel, and the action mechanism and effect are remarkably different from those of a DHA-based scheme in the prior art. Meanwhile, the ATT can obviously relieve lipid deposition of liver cells, improve lipid metabolism disorder, effectively relieve liver cell oxidative stress and lipid peroxidation damage induced by lipid deposition, and prevent the cells from triggered apoptosis.

The invention discloses a method for obtaining, activating and amplifying natural killer cells through iPSC differentiation induction, and relates to the technical field of stem cell biology, the method for obtaining, activating and amplifying natural killer cells through iPSC differentiation induction comprises the following steps: S1, preparing and inoculating iPSC cells; s2, differentiating the iPSC to a mesoderm; s3, the mesoderm cells are differentiated to CD34 + hematopoietic endothelial cells; s4, differentiating the CD43 < + > / CD45 < + > hematopoietic stem cells into the iNK cells; s5, maturation of the iNK cells; s6, activating and amplifying the iNK cells; in the step S1, cells are resuspended by using a fresh E8 complete culture medium and are inoculated into a porous culture plate; a plurality of induction culture media are used in the culture process; by adopting a porous culture plate and using an E8 complete culture medium to resuspend cells, efficient inoculation and primary culture of iPSC are realized, and the survival rate and amplification efficiency of cells are improved; the differentiation process of the iPSC towards the mesoderm, the hematopoietic endothelial cells and the CD34 + hematopoietic stem cells is optimized by using various induction culture media, and the differentiation efficiency is improved.

Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

To provide a pharmaceutical composition for treating BCMA-expressing cancer.SOLUTION: Provided is a medicament comprising a first therapeutic agent and a second therapeutic agent for use in treating cancer and / or a cancer-related disease in a subject. In some aspects, the first therapeutic agent is a B-cell maturation antigen (BCMA) - specific therapeutic agent. In some aspects, the second therapeutic agent is an anti-PD-1 antibody, an anti-PD-Ll antibody, an immunomodulator, or a gamma secretase inhibitor (GSI).SELECTED DRAWING: None